FindTrial
Sign In

Activated microglia and alpha 7 nicotinic acetylchorine receptors in schizophrenia: A PET study (for smoker)

Activated microglia and alpha 7 nicotinic acetylchorine receptors in schizophrenia: A PET study (for smoker) - Evaluation for activated microglia and alpha 7 nicotinic receptors using PET in schizophrenia patients (for smoker)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000038171
Enrollment
20
Registered
2019-10-07
Start date
2019-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

PET, 11C-DPA713 (activated microglia) 5MBq/kg iv PET, 11C-MeQAA (alpha 7 nicotinic receptors) 5MBq/kg iv

Sponsors

Hamamatsu University Hospital
Lead Sponsor
Hamamatsu Photonics K.K. Hamamatsu Medical Photonics Foundation, Hamamatsu Medical Imaging Center
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Diagnosed as schizophrenia on DSM-5 - Full IQ above 70 measured with Wechsler Adult Intelligent Scale-III - Smoker

Exclusion criteria

Exclusion criteria: - With past or current history of serious medical illness and/or brain organic diseases - History of alcoholics or substance abuse or addiction - In pregnancy - No family support - Taking antiallergic or anticholinergic drugs - Difficult for taking MRI imaging

Design outcomes

Primary

MeasureTime frame
The binding potential of both 11C-DPA713 and 11C-MeQAA in hippocampus and prefrontal cortex—

Secondary

MeasureTime frame
cognitive function test (Cog state, TMT, stroop, VFT) Positive and Negative Symptom Scale (PANSS)—

Countries

Japan

Contacts

Public ContactTomoyasu Wakuda

Hamamatsu University Hospital Department of Psychiatry

wakuda@hama-med.ac.jp0534352295

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026